Abstract: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4143-151-specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

Abstract: The present invention discloses a cell system, as a host cell to be infected with an F gene-deficient virus, which can constitutively and stably express the F protein, and a method for producing an F gene-deficient virus by utilizing the cell. A non-proliferative human parainfluenza type 2 virus vector is produced by co-culturing an F gene-deficient human parainfluenza type 2 virus with a Vero cell having the F gene of human parainfluenza type 2 virus in such a manner that the F gene is non-inducibly expressed, and isolating viral particles from a culture supernatant.

Abstract: A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA.

Abstract: Provided is siRNA effective for the treatment of fibrosis and a pharmaceutical containing the siRNA. An siRNA having a full length of 30 or fewer nucleotides and targeting a sequence consisting of 17 to 23 consecutive bases selected from the group consisting of bases at positions 1285 to 1318, bases at positions 1398 to 1418, bases at positions 1434 to 1463, bases at positions 1548 to 1579, bases at positions 1608 to 1628, bases at positions 1700 to 1726, bases at positions 1778 to 1798, bases at positions 1806 to 1826, and bases at positions 1887 to 1907 of SEQ ID NO: 1.

Abstract: A protected anode including: an anode including lithium or capable of reversibly incorporating lithium ions; and a lithium ion-conductive protective layer on the anode and including a ceramic composite represented by Formula 1: Li1+aAlbGe2?cMdP3+eO12+f??Formula 1 wherein M is at least one element selected from titanium (Ti), zirconium (Zr), and germanium (Ge), 0?a?1, 0?b?1, 0?c?1, 0?d?0.5, 0?e?0.1, and 0?f?1.

Abstract: Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.

Abstract: [PROBLEMS] To provide a method for preparation of recombinant proteoliposomes suitable for diagnostic applications, a detection plate coated with the recombinant proteoliposomes, a detection kit and so on. [PROBLEM-SOLVING MEANS] Recombinant proteoliposomes are prepared by fusion of budded virus particles of a recombinant baculovirus, expressing a target membrane receptor (such as human thyroid-stimulating hormone receptor, acetylcholine receptor, insulin receptor, ?1 adrenergic receptor, asialoglycoprotein receptor, etc., each participating in an autoantibody-related disease), with liposomes. Compared with the recombinant baculoviruses, these proteoliposomes have an improved ability to bind to an autoantibody and makes it possible to produce easily a kit for its detection.

Abstract: A method for manufacturing a linear-chain beta-1,3-glucan is disclosed that comprises polymerizing glucose-1-phosphate serving as a substrate by contacting the glucose-1-phosphate with a beta-1,3-glucan phosphorylase derived from a species in the genus Ochromonas. A laminarioligosaccharide may be added to serve as a primer. A linear-chain beta-1,3-glucan having a degree of polymerization between about 30 to 70 is also disclosed.

Abstract: Disclosed are: a polyorganosiloxane composition which can be cured into a product having high strength and has little influence on the environment; and a cured product of the polyorganosiloxane composition. Specifically disclosed are: a polyorganosiloxane composition comprising (A) a polyorganosiloxane in which at least one end in the molecule is modified with a silanol, (B) a titanium alkoxide in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane, and (C) an ?-hydroxycarbonyl compound or a hydroxycarboxylic acid ester in an amount of 0.01 to 2 moles relative to 1 mole of the polyorganosiloxane; and a cured product of the polyorganosiloxane composition.

Abstract: Disclosed is an organosiloxane composition which can be produced at low cost and is usable for bonding of glasses, metals and resins. The organosiloxane composition can provide a cured product exhibiting excellent heat resistance and cold resistance, while having high strength and high transparency. Specifically disclosed is a polyorganosiloxane composition containing (A) a polyorganosiloxane wherein at least one end of each molecule is modified with a silanol group, and (B) 0.5-4.0 moles of a metal alkoxide per 1 mole of the polyorganosiloxane, wherein the mean molecular weight (Mw) of the polyorganosiloxane according to the mass fraction is not more than 1,000. Also specifically disclosed are a cured product of the composition and a method for producing the composition.

Abstract: A lithium air battery including an electrolyte including lithium ion conductive polymers and lithium salts between a positive electrode and a lithium ion conductive solid electrolyte membrane. The lithium ion conductive polymers are hydrophilic matrix polymers.

Abstract: In an apparatus, a predicting unit uses, as an initial value of a controlled variable, at least one of a first measured value of the controlled variable and a second measured value of a physical variable expressed as a function of the controlled variable. The predicting unit predicts, based on the initial value of the controlled variable, a value of the controlled variable when a driving mode of a switching element of a power converter is set. A driving unit has an integral element and determines, based on an output of the integral element to which a deviation between the predicted value of the controlled variable and a command value of the controlled variable is inputted, an actual driving mode of the switching element to thereby drive the switching element in the determined driving mode.

Abstract: A polypeptide comprising a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 5 of Sequence Listing or a polypeptide consisting of an amino acid sequence having deletion, addition, insertion or substitution of one to several amino acid residues in the sequence, the polypeptide being capable of constituting an HLA-A24-restricted, MAGE-A4143-151-specific T cell receptor together with a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 2 of Sequence Listing.

Abstract: The present invention provides an artificial scaffolding material for retaining proteins suitable for placing contiguously one species or two or more species of proteins such as enzymes. To this end, the artificial scaffolding material for retaining proteins is provided with a cell and scaffolding proteins heterologous to the cell and placed on the surface layer side of the cell at an extent that allows aggregation properties to be conferred to the cell, and provided with a plurality of non-covalently binding protein-binding domains arranged in tandem.

Abstract: A negative electrode for a lithium secondary battery that includes an organic-inorganic hybrid protective layer where the lithium ion conductivity of a polymer included in the organic-inorganic hybrid protective layer is about 10?4 S/cm or less, a method of manufacturing the same, and a lithium secondary battery employing the same.

Abstract: Disclosed is a intranasal spray-type tuberculosis vaccine, which has a high prophylactic effect on human tuberculosis, particularly adult tuberculosis. The nebulizable tuberculosis vaccine for intranasal administration comprises a paramyxovirus gene (particularly rhPIV2) having, integrated therein, a gene encoding an ? antigen derived from an acid-fast bacterium (e.g., an ? antigen derived from Mycobacterium kansasii or Mycobacterium bovis BCG), an analogue of the gene, or a variant of the gene which has an equivalent function to that of the gene.

Abstract: The present invention relates to a T lymphocyte having an activity to induce a T lymphocyte recognizing an antigen and a technique to use the T lymphocyte.

Abstract: A lithium ion conductor, a method of preparing the same, and a lithium air battery including the lithium ion conductor. The lithium ion conductor includes a phosphorus-based compound having a characteristic peak at a Raman shift of about 720˜770 cm?1 on a Raman spectrum of the phosphorus-based compound.

Abstract: The present invention provides anti-cancer agents comprising protein C inhibitor (PCI) or derivatives thereof as an active ingredient. The anti-cancer agents of the present invention have activities of suppressing cancer cell growth, and cancer metastasis, infiltration, and angiogenesis. Further, the present invention has shown that derivatives containing a heparin-binding domain of PCI inhibit the growth, metastasis and angiogenesis of cancer cells. Therefore, according to the present invention, PCI or derivatives thereof are useful for inhibiting the growth, metastasis and angiogenesis of cancer.